The impacts of the COVID-19 pandemic on treatment-resistant schizophrenia patients having followed virtual reality therapy or cognitive behavioural therapy: a content analysis

Alexandre Hudon, Nayla Léveillé, Katerina Sanchez-Schicharew, Laura Dellazizzo, Kingsada Phraxayavong, Alexandre Dumais, Alexandre Hudon, Nayla Léveillé, Katerina Sanchez-Schicharew, Laura Dellazizzo, Kingsada Phraxayavong, Alexandre Dumais

Abstract

Purpose: The COVID-19 pandemic led to exacerbation of mental health symptoms and deterioration in psychological well-being in individuals suffering from schizophrenia. The primary objective of this study is to evaluate the impacts of the COVID-19 pandemic on patients suffering from treatment-resistant schizophrenia (TRS) with auditory verbal hallucinations (AVH) having undergone virtual reality therapy (VRT) or cognitive behavioural therapy (CBT) on their symptomatology. The secondary objective is to identify the differences and similarities in relation to the response to the COVID 19 pandemic between these two groups of patients.

Methods: Qualitative analysis of semi-structured interviews was conducted with 42 patients suffering from TRS who had previously followed VRT or CBT. All interviews were recorded, transcribed, and analysed.

Results: Four themes emerged in this study: Psychotherapeutic Interventions, Impact of COVID-19 and Public health and safety policies, Substance use and Psychiatric follow-up. Participants from both groups reported that their therapy was beneficial in controlling AVH. Patients having followed CBT reported more depressive symptoms whereas patients having followed VRT reported more anxious symptoms.

Conclusions: This study offers a first qualitative insight in patients suffering from TRS and the impacts of COVID-19 on them and opens the door to the protective factors of CBT and VRT for this specific population.

Trial registration: ClinicalTrials.gov NCT03585127.

Keywords: COVID-19; avatar therapy; cognitive behavioural therapy; schizophrenia; virtual reality therapy.

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

References

    1. Šimunović Filipčić I, Filipčić I.. Schizophrenia and physical comorbidity. Psychiatr Danub. 2018;30(4):152–157.
    1. Nucifora FC Jr, Woznica E, Lee BJ, et al. . Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.
    1. Alegría M, NeMoyer A, Falgàs Bagué I, et al. . Social determinants of mental health: where we are and where we need to go. Curr Psychiatry Rep. 2018;20(11):95.
    1. Saladino V, Algeri D, Auriemma V.. The psychological and social impact of covid-19: new perspectives of Well-Being. Front Psychol. 2020;11:577684.
    1. Wu T, Jia X, Shi H, et al. . Prevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord. 2021;281:91–98.
    1. Caqueo-Urízar A, Urzúa A, Ponce-Correa F, et al. . Psychosocial effects of the COVID-19 pandemic on patients with schizophrenia and their caregivers. Front Psychol. 2021;12:729793.
    1. Ornell F, Borelli W, Benzano D, et al. . The next pandemic: impact of COVID-19 in mental healthcare assistance in a nationwide epidemiological study. Lancet Reg Health Am. 2021;4:100061.
    1. Chen KL, Brozen M, Rollman JE, et al. . How is the COVID-19 pandemic shaping transportation access to health care? Trans Res Interdiscip Perspect. 2021;10:100338.
    1. Nemani K, Li C, Olfson M, et al. . Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380–386.
    1. Suthaharan P, Reed E, Leptourgos P, et al. . Paranoia and belief updating during the COVID-19 crisis. Nat Hum Behav. 2021;5(9):1190–1202.
    1. Smith CM, Gilbert EB, Riordan PA, et al. . COVID-19-associated psychosis: a systematic review of case reports. Gen Hosp Psychiatry. 2021;73:84–100.
    1. Strauss GP, Macdonald KI, Ruiz I, et al. . The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022;272(1):17–27.
    1. Fleischmann E, Dalkner N, Fellendorf FT, et al. . Psychological impact of the COVID-19 pandemic on individuals with serious mental disorders: a systematic review of the literature. World J Psychiatry. 2021;11(12):1387–1406.
    1. Vita A, Minelli A, Barlati S, et al. . Treatment-resistant schizophrenia: genetic and neuroimaging correlates. Front Pharmacol. 2019;10:402.
    1. González-Ortega I, Vega P, Echeburúa E, et al. . A multicentre, randomised, controlled trial of a combined clinical treatment for first-episode psychosis. Int J Environ Res Public Health. 2021;18(14):7239.
    1. Brockman R, Kiernan M, Brakoulias V, et al. . The relationship between cognitive behavioural therapy maintenance processes, emotional distress, and positive psychotic symptoms: evidence that CBT is "not a Quasi-Neuroleptic.” J Cogn Psychother. 2014;28(2):101–116.
    1. Thomas N, Hayward M, Peters E, et al. . Psychological therapies for auditory hallucinations (voices): current status and key directions for future research. Schizophr Bull. 2014;40(4):S202–S212.
    1. Bisso E, Signorelli MS, Milazzo M, et al. . Immersive virtual reality applications in schizophrenia spectrum therapy: a systematic review. Int J Environ Res Public Health. 2020;17(17):6111.
    1. Craig TK, Rus-Calafell M, Ward T, et al. . AVATAR therapy for auditory verbal hallucinations in people with psychosis: a single-blind, randomised controlled trial [published correction appears in lancet psychiatry. 2017 nov 29]. Lancet Psychiatry. 2018;5(1):31–40.
    1. Dellazizzo L, Potvin S, Phraxayavong K, et al. . One-year randomized trial comparing virtual reality-assisted therapy to cognitive-behavioural therapy for patients with treatment-resistant schizophrenia. NPJ Schizophr. 2021;7(1):9.
    1. Kotlarska K, Wielgus B, Cichocki Ł.. Phenomenology of the COVID-19 pandemic experience in patients suffering from chronic Schizophrenia-A qualitative analysis. Int J Environ Res Public Health. 2021;19(1):56.
    1. van Dis EAM, van Veen SC, Hagenaars MA, et al. . Long-term outcomes of cognitive behavioural therapy for Anxiety-Related disorders: a systematic review and meta-analysis [published correction appears in JAMA psychiatry. 2020 jul 1;77(7):768]. JAMA Psychiatry. 2020;77(3):265–273.
    1. du Sert OP, Potvin S, Lipp O, et al. . Virtual reality therapy for refractory auditory verbal hallucinations in schizophrenia: a pilot clinical trial. Schizophr Res. 2018;197:176–181.
    1. Chun Tie Y, Birks M, Francis K.. Grounded theory research: a design framework for novice researchers. SAGE Open Med. 2019;7:2050312118822927.
    1. Chomczynski P. QDA MINER – the mixed method solution for qualitative analysis by provalis research. QSR. 2008;4(2):126–129.
    1. Scott’s Pi . The SAGE encyclopedia of communication research methods. Thousand Oaks (CA): SAGE Publications; 2017.
    1. Dellazizzo L, Potvin S, Phraxayavong K, et al. . Exploring the benefits of virtual Reality-Assisted therapy following Cognitive-Behavioural therapy for auditory hallucinations in patients with Treatment-Resistant schizophrenia: a proof of concept. J Clin Med. 2020;9(10):3169.
    1. Rathod S, Phiri P, Kingdon D.. Cognitive behavioural therapy for schizophrenia. Psychiatr Clin North Am. 2010;33(3):527–536.
    1. Yao H, Chen JH, Xu YF.. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21.
    1. Gobbi S, Płomecka M, Ashraf Z, et al. . Worsening of preexisting psychiatric conditions during the COVID-19 pandemic. Front Psychiatry. 2020;11:581426.
    1. Puangsri P, Jinanarong V, Wattanapisit A.. Impacts on and care of psychiatric patients during the outbreak of COVID-19. Clin Pract Epidemiol Ment Health. 2021;17:52–60.
    1. Peters E, Crombie T, Agbedjro D, et al. . The long-term effectiveness of cognitive behavior therapy for psychosis within a routine psychological therapies service. Front Psychol. 2015;6:1658.
    1. Sivec HJ, Montesano VL.. Cognitive behavioural therapy for psychosis in clinical practice. Psychotherapy (Chic). 2012;49(2):258–270.
    1. Aali G, Kariotis T, Shokraneh F.. Avatar therapy for people with schizophrenia or related disorders. Cochrane Database Syst Rev. 2020;5(5):CD011898.
    1. Kocur M, Dechant M, Wolff C, et al. . Computer-Assisted Avatar-Based treatment for dysfunctional beliefs in depressive inpatients: a pilot study. Front Psychiatry. 2021;12:608997.
    1. Vallecillo G, Perelló R, Güerri R, et al. . Clinical impact of COVID-19 on people with substance use disorders. J Public Health (Oxf). 2021;43(1):9–12.
    1. Ornell F, Moura HF, Scherer JN, et al. . The COVID-19 pandemic and its impact on sub-stance use: Implications for prevention and treatment. Psychiatry Res. 2020;289:113096.
    1. Correll C, Chepke C, Gionfriddo P, et al. . The post COVID-19 healthcare landscape and the use of long-acting injectable an-tipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry. 2022;22(1):32.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj